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Introduction: Neurofibrillary tangles (NFT) composed of Tau are hallmarks of neurodegeneration in Alzheimer
disease. Transgenic mice expressing full-length pro-aggregant human Tau (2N4R Tau-ΔK280, termed TauΔK) or its
repeat domain (TauRD-ΔK280, TauRDΔK) develop a progressive Tau pathology with missorting, phosphorylation,
aggregation of Tau, loss of synapses and functional deficits. Whereas TauRDΔK assembles into NFT concomitant with
neuronal death, TauΔK accumulates into Tau pretangles without overt neuronal loss. Both forms cause a comparable
cognitive decline (with onset at 10mo and 12mo, respectively), which is rescued upon switch-off of transgene expression.
Since methylene blue (MB) is able to inhibit Tau aggregation in vitro, we investigated whether MB can prevent or rescue
Tau-induced cognitive impairments in our mouse models. Both types of mice received MB orally using different
preventive and therapeutic treatment protocols, initiated either before or after disease onset. The cognitive status of the
mice was assessed by behavior tasks (open field, Morris water maze) to determine the most successful conditions for
therapeutic intervention.
Results: Preventive and therapeutic MB application failed to avert or recover learning and memory deficits of TauRDΔK
mice. Similarly, therapeutic MB treatment initiated after onset of cognitive impairments was ineffective in TauΔK
mice. In contrast, preventive MB application starting before onset of functional deficits preserved cognition of TauΔK
mice. Beside improved learning and memory, MB-treated TauΔK mice showed a strong decrease of insoluble Tau, a
reduction of conformationally changed (MC1) and phosphorylated Tau species (AT180, PHF1) as well as an upregulation
of protein degradation systems (autophagy and proteasome). This argues for additional pleiotropic
effects of MB beyond its properties as Tau aggregation inhibitor.
Conclusions: Our data support the use of Tau aggregation inhibitors as potential drugs for the treatment of AD and
other tauopathies and highlights the need for preventive treatment before onset of cognitive impairments.
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Alzheimer disease (AD) is a fatal dementia with progressive
accumulation of protein aggregates composed of amyloid-
beta (Aβ) and the microtubule-associated Tau protein in
brain structures relevant for learning and memory [1]. Des-
pite much progress made in recent years, the details of the* Correspondence: mandelkow@dzne.de
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unless otherwise stated.neurotoxic cascade are still a matter of debate. However, it
is assumed that the accumulation of protein aggregates
is closely linked to neurotoxicity and degeneration.
Current treatment options for AD are still limited to
acetylcholinesterase inhibitors (donepezil, galantamine,
rivastigmine), NMDA (N-methyl-D-aspartate) receptor
antagonists (memantine) or other supportive strategies
ameliorating the symptoms, rather than treating the
underlying causes of neurodegeneration [2]. Recently, a
number of promising drug candidates targeting different
stages of Aβ pathology failed in clinical trials [3,4]. Intral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of Aβ pathology) correlates closely with loss of synapses
and neurons, the best correlate of cognitive decline [5-7].
As a result, Tau has become a promising target for thera-
peutic intervention.
The process of Tau aggregation, from oligomers to
neurofibrillary tangles (NFT) is suspected to induce neu-
rodegeneration. Support for this hypothesis came from
Tau transgenic mouse models expressing aggregation-
prone Tau mutants. Examples are P301S [8-10], P301L
[11-13] and ΔK280 [14,15], or, as negative controls,
non-aggregating Tau mutants, e.g. ΔK280-PP [16,17].
Aggregation-prone Tau mutants were identified from
cases of sporadic and hereditary forms of frontotemporal
dementia (FTD). The deletion mutation ΔK280 was ori-
ginally detected in a sporadic FTD case [18,19] and more
recently in an Alzheimer patient [20].
In mice, expression of either full-length pro-aggregant
human Tau-ΔK280 (TauΔK) or its repeat domain
(TauRDΔK) under control of the CaMKIIα promoter leads
to progressive neuropathology. Both models share several
common aspects, including the formation of co-aggregates
composed of exogenous human and endogenous mouse
Tau, loss of synapses accompanied by functional deficits
such as cognitive decline and electrophysiological impair-
ments. The most important similarity of both models
is that the functional deficits can be recovered after
switching-off the expression of pro-aggregant Tau. As a
consequence of switch-off, Tau co-aggregates undergo
structural reorganization with release and clearance of ex-
ogenous Tau, whereas the aggregated endogenous mouse
Tau persists for several months. By contrast, the two
models clearly differ in the onset and severity of Tau path-
ology. TauRDΔK is the more toxic Tau species, presumably
because of its greater propensity for aggregation based on
β-structure. Thus, expression of TauRDΔK leads to early
development of silver-positive NFT and neuronal loss in-
side the hippocampus formation (~5mo), which are nearly
absent in TauΔK mice. In addition cognitive decline and
loss of synapses occurs earlier in TauRDΔK (~10mo) than
in TauΔK mice (~12mo).
Despite the variations between the TauRDΔK and TauΔK
mouse models, the studies summarized above share the
essential fact that tauopathies as such are largely revers-
ible, provided that the amyloidogenic Tau is removed
[14,15]. Thus strategies and substances counteracting Tau
aggregation are promising candidates for the treatment of
AD and other tauopathies.
Several screens identified low molecular weight
compounds, which act as Tau aggregation inhibitors
[21-24]. One compound of particular interest is methy-
lene blue (MB). The inhibitory effect of MB applies not
only to Tau aggregation [24,25] but also to other pro-
teins involved in neurodegeneration such as huntingtin[26], TDP-43 and alpha-synuclein [27], Aβ [28] and
prion protein [29]. MB is an FDA approved drug and
has a long history of medical use, mainly as an antisep-
tic and anti-malaria compound. Biochemically, MB is a
bioavailable member of the phenothiazine family with high
water solubility. It is a redox-cycling compound, relatively
non-toxic and able to pass the blood-brain barrier [30,31].
The first anti-Tau therapy with MB in humans was re-
ported by Wischik et al. in 2008 [32]. In this phase 2 clin-
ical trial, a daily dose of 3x 60 mg Rember™ (a derivative of
the oxidized form of MB) over 1 year appeared to show a
slow-down of cognitive decline in mild and moderate
AD patients. Since none of these studies have been
published in a peer-reviewed journal, a skeptical atti-
tude towards the presented results remains in the field.
Meanwhile Rember™ was replaced by its more sophisti-
cated successor LMTX™, which is optimized in terms of
enhanced tolerability and higher absorption in the intes-
tine as it contains the reduced “leuco” form of MB [33].
Up to now three phase-3 trials have been announced for
LMTX™, one for the treatment of bvFTD or Pick disease
and two studies for AD. First results are expected for late
2015 or early 2016 (as stated by TauRx Therapeutics [34]).
In parallel a number of preclinical studies in various
model organisms were performed to elucidate MB’s
neuroprotective mechanism of action. However, the re-
sults published remain controversial. While MB ame-
liorates the neurotoxic phenotype in a C. elegans model
of tauopathy with aggregated Tau in neurons [35], it
was reported to be ineffective in zebrafish expressing
P301L mutant Tau without aggregated Tau [36]. In mice,
MB showed beneficial phenotypic effects in models of
Huntington disease [26] and in models of AD [37-39], but
failed in models of amyotrophic lateral sclerosis [40,41]. In
addition MB’s effect on neuronal pathology is still
under debate. In case of Tau pathology there is a de-
bate on whether MB acts on soluble or insoluble Tau
species [39,42,43] and whether additional mechanisms
such as enhancing general protein clearance via au-
tophagy or proteasomes, improving energy metabolism,
or other effects on ATP/GTP binding proteins play a
role [38,44-46].
The present study aims to contribute to the discus-
sion how MB can ameliorate Tau-induced pathological
changes and (more importantly) cognitive impairment
in inducible pro-aggregant mice. In addition our pur-
pose is to refine treatment paradigms with respect to
treatment initiation, concentration and duration. To
this end pro-aggregant TauΔK and TauRDΔK mice were
treated orally with MB using different long- and short-
term treatment protocols to determine the most suc-
cessful conditions for therapeutic intervention. The
effect of MB on cognition was evaluated in different
behavior tasks (open field and Morris water maze) and
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were compared to gain insights into MB’s mode of
action.
Materials and methods
Generation of pro-aggregant Tau transgenic mice
Transgenic mice expressing pro-aggregant human
full-length Tau (2N4R, Tau441, with deletion mutant
ΔK280, 441-1 = 440 amino acids, here termed TauΔK) or
pro-aggregant Tau repeat domain (construct K18, 4R,
residues 244-372, termed TauRDΔK) were generated as
described [16,17] (Additional file 1: Figure S1). Briefly,
responder mice carrying either the Tau-transgene to-
gether with a luciferase reporter were crossbred with
the CaMKIIα-tTA transactivator mice [47] to obtain
double-transgenic mice with constitutive expression of
luciferase and pro-aggregant TauΔK or TauRDΔK. All
bigenic offspring were heterozygous and had an identi-
cal C57BL/6 genetic background. Non-transgenic litter-
mates were used as controls. The transgene expression
of bigenic mice started roughly around birth (0mo)
concomitant with the onset of CaMKIIα activity. The
expression was measured in vivo by bioluminescence
imaging of luciferase activity. All animal procedures
were approved in accordance with the German Animal
Welfare Act.
In vivo bioluminescence imaging of luciferase activity
In vivo bioluminescence imaging to quantify luciferase
activity and estimate expression strength of Tau trans-
genes was performed using an Ivis Lumina II system
(Caliper Life Science) as described [15]. Briefly, mice
received an intraperitoneal injection of 150 mg/kg D-
luciferin/PBS (Caliper Life Science) 10 min prior to
imaging and were anesthetized using 2% isoflurane
(Abbott). A sequence of images was collected using a
highly sensitive CCD camera. The bioluminescence
emission was analyzed and quantified by the Living
Image 4.0 software (Caliper Life Science).
Oral methylene blue treatment of Tau transgenic mice
Methylene blue (MB, C16H18CIN3S * 3 H2O, Sigma) was
administered ad libitum via the drinking water supple-
mented with saccharin (Huxol, 1 tablet per 200 ml).
Mice received a daily MB-dose of 40 or 20 mg/kg based
on a daily drinking volume of ~5-6 ml and a body
weight of 25-35 g. The concentration of the MB drinking
solution was 0.25 mM or 0.5 mM, respectively. TauΔK
mice were treated using a daily dose of 20 mg/kg MB. In
all cases Tau expression started at birth (~0mo); one
group of TauΔK mice received MB for 14.5mo starting at
1.5mo of age. A second group was administered MB for
6mo, starting at 9mo of age and a third group received
MB for 3mo, starting at 15mo of age. TauRDΔK micereceived a daily dose of 20 mg/kg MB for 3mo and
14.5mo starting at 12mo or 1.5mo of age, respectively.
Another group of TauRDΔK mice was treated with
40 mg/kg MB for 3mo, starting at 12mo of age. MB-
treated groups were accompanied by groups of vehicle
treated (H2O + saccharin) Tau transgenic littermates and
by groups of wild-type littermates (MB or vehicle
treated). Each group was composed of 6-11 age and gen-
der matched animals.
Behavior tasks
Housing conditions: prior to behavior experiments, mice
were single-housed under standard conditions with food,
water and MB ad libitum in a room with inverted 12 h
light/dark cycle to assure testing in the nocturnal phase
of the animals.
Open field test: the open field consists of a 50 x 50 cm
arena divided into 20 x 20 cm center, a 5 cm wall zone
and a 10 cm border zone. Each mouse was placed into
the center of the box and could freely explore the arena
for 15 min while being tracked by a video system
(Viewer II, Biobserve). The following parameters were
analyzed: activity, distance moved, mean velocity, time
spent in the center zone and distance to wall. Activity
was defined as amount of active time (%) during the dur-
ation of stay, in which the mouse’s movement speed
exceeded the activity threshold. The activity threshold
defines a certain velocity limit to distinguish active from
inactive behavior (1 cm/s).
Morris water maze (MWM): before starting the MWM
experiment, a 2 days pretraining protocol was conducted
to habituate the mice to swimming and climbing onto a
hidden platform. To avoid any interference with the
MWM learning, the pretraining was performed in a dif-
ferent room and apparatus than used for the MWM.
Spatial memory abilities were examined in the standard
hidden-platform acquisition and retention version of the
Morris water maze [48]. A 180 cm circular pool was
filled with water opacified with non-toxic white paint
(Biofa Primasol 3011). The tank was divided into four
quadrants: target (T), right adjacent (R), opposite (O),
and left adjacent (L). A 15 cm round platform was hidden
1 cm beneath the surface of the water at a fixed position
in the center of the target quadrant. The pool was sur-
rounded by landmarks attached to the walls to facilitate
orientation. Each mouse performed 4 swimming trials per
day (maximum duration 90s, 10 min inter-trial interval)
for five consecutive days. The time required to locate the
hidden platform (escape latency), path length and swim-
ming speed were determined. On acquisition day 3, 4, 5,
as well as 2 days after the end of acquisition, a probe trial
was conducted without platform. Acquisition and probe
trials were recorded and analyzed by the Viewer II video
tracking system (Biobserve).
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Sarcosyl-extraction, total protein preparation and west-
ern blots were performed as described previously
[14,15]. Depending on the 1st antibody, 2-20 μg of total
protein or 3 μl of sarcosyl extraction lysates from brain
tissue were loaded for the detection with pan-Tau anti-
body K9JA (1:20000, Dako A-0024), the human Tau spe-
cific antibody TauY9 (1:2000, Enzo), phospho-Tau
antibodies 12E8 (pSer262/pSer356, 1:500, Elan), PHF1
(pSer396/pSer404, 1:500, gift from Dr. P. Davies) and
antibodies against synaptophysin (1:20000, Sigma),
synapsin1 (1:2000, Novus Biologicals), PSD95 (1:2000,
Dianova), Beclin (1:10000, Santa Cruz), HSC70 (1:10000,
Abcam), lamp2a (1:2000, Abcam), PSMD13 (1:2000,
Abcam). Blots were normalized by the concentration of
β-actin (1:20000, Sigma).
Histology
Immunohistochemistry was performed on 5 μm paraffin
sections as described [14,15]. The following antibodies
were used for light microscopy: MC1 (conformational epi-
tope, aa 5-15 + 312-322, 1:10, gift of Dr. P. Davies, Albert
Einstein College, NY) and AT180 (pThr231/pSer235,
1:1000, Pierce). Secondary antibodies as well as the avidin-
biotinylated peroxidase complex were provided by the
Vectastain Universal Elite ABC kit (Vector laboratories)
and DAB (Dako) was used to visualize the antibody
labeling. Gallyas silver impregnation was performed as
described [14,15]. Immunofluorescence: the primary
mouse monoclonal OXPHOS antibody cocktail (1:250,
MitoScience) followed by a secondary anti-mouse DyLight
650 antibody (1:500, Thermo Fisher Scientific) was ap-
plied. Nuclei counterstain was performed with Syto13
(1:4000, Life Technologies GmbH). Stainings imaged by a
LSM510 Meta confocal microscope (Zeiss) using lasers,
beam splitters, and filters according to the fluorophores.
Statistics
Open field test: MB-treated, untreated and control
groups were compared by one-way ANOVA with post
hoc Newman-Keuls multiple comparison test. Morris
water maze: MB-treated, untreated and control groups
were compared by two-way repeated ANOVA followed
by a post hoc Fisher LSD multiple comparison test. Aster-
isks indicate differences between treated and untreated
TauΔK mice (MWM acquisition). For analysis of probe
trials a two-tailed t-test against chance level (25%) or a
one-way ANOVA with post-hoc Newman-Keuls mul-
tiple comparison test was done. Protein amounts were
compared by one way ANOVA with post hoc Newman-
Keuls multiple comparison test or by an unpaired two-
tailed t-test. Numbers of samples are indicated in figure
legends. All data are presented as group mean values
with standard error of mean (SEM), the accepted levelof significance was p < 0.05. Statistical comparisons
were performed using STATISTICA 10.0 software
(StatSoft), graphs were designed using Prism 5.0 soft-
ware (GraphPad). *: p < 0.05, **: p < 0.01, ***: p < 0.001.
Results
Characteristics of pro-aggregant Tau transgenic mice
Inducible mice with constant expression of full-length
pro-aggregant TauΔK or repeat domain pro-aggregant
TauRDΔK develop a progressive neuropathology includ-
ing prominent cognitive deficits. Importantly, cognitive
deficits as well as synaptic impairments recover after
switching off the expression of human Tau [14,15], dem-
onstrating that Tau-induced pathology can be reversed
in principle. These studies provide the rationale for
treatment of pro-aggregant mice using Tau-directed
drugs.
From 3 months (mo) of age onwards (or after 3mo of
Tau expression), repeat domain TauRDΔK mice show a
pronounced neuropathology, especially in terms of Tau
aggregation and neuronal death. By comparison, the
brain pathology is much less pronounced in full-length
TauΔK mice. These mice develop a pre-tangle pathology
indicated by the conformation-dependent antibody MC1
[49] but lack a silver-positive NFT pathology and neur-
onal loss in the hippocampus. The difference is consist-
ent with the fact that TauRDΔK lacks the flanking
regions (Additional file 1: Figure S1), which leads to a
higher β-propensity, causing efficient aggregation and a
stronger neurotoxicity than full-length TauΔK at compar-
able expression levels. Note that TauRDΔK cannot react
with antibody MC1, since it lacks part of the epitope;
the same holds for other diagnostic antibodies (e.g. AT8)
with epitopes outside the repeat domain. Therefore, the
appearance of MC1 or AT8 reactivity in TauRDΔK mice
originates from endogenous mouse Tau, which has been
transformed to a pathological state, triggered by exogen-
ous TauRDΔK. By contrast, the epitope of antibody 12E8
(pS262 + pS356) lies within the repeats and is present in
all Tau variants.
Due to the specific design of the transgenic DNA the
expression of human TauΔK and TauRDΔK can be deduced
from luciferase activity by bioluminescence imaging (BLI)
in living mice. This opens the possibility to preselect
animals with comparable Tau expression prior to exper-
iments in order to reduce inter-individual variations,
which is important since Tau levels influence the severity
of pathology [50].
Pharmacokinetic properties of MB in mice
To check bioavailability and lifetime of MB in mice, MB
levels in plasma and brain were measured after intraven-
ous (i.v.) application of 30 mg/kg MB or oral application
of 45 mg/kg MB (Additional file 2: Figure S2) in wild-type
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evaluated by quantification of tetramethylthioninium-ion
(TMT-ion) concentrations using liquid chromatography -
mass spectrometry (LC-MS/MS). TMT-ion equals MB
without chloride and 3*H2O.
After i.v. administration, peak concentrations in plasma
and brain were observed at 5 to 15 min post application
and pharmacokinetic analyses over 24 h revealed MB
half-lives of t1/2 = 4.4 h in plasma and t1/2 = 3.0 h in brain
(Additional file 2: Figure S2a). Intravenous application of
MB led to a reduced general condition and apathy of the
mice, which may point to an acute toxic effect of the bolus.
In contrast, oral administration of MB was well-tolerated
and led to peak concentrations in plasma and brain within
the first 2 hours post application. Pharmacokinetic ana-
lyses over 24 h exhibited MB half-lives of t1/2 = 4.7 h in
plasma and t1/2 = 30.6 h in brain. The oral bioavailabil-
ity was determined at ~18% (Additional file 2: Figure
S2b). Furthermore, the results show a concentration of
MB inside the brain, with ~30-fold and ~60-fold higher
MB levels in brain tissue compared to plasma at 24 h
post i.v. or oral application, respectively.
MB application strategies
The goal of the study was to optimize MB treatment condi-
tions in order to get the maximum beneficial effect on
learning and memory performance of Tau transgenic
mice. To this end we followed different treatment strategies
(Figure 1). The major difference between the various treat-
ment protocols is the initial time point of intervention,
namely before or after onset of cognitive impairments,
which start typically at ~12mo of age in TauΔK mice and at
~10mo of age in TauRDΔK mice. The key question was,
how much Tau pathology can be allowed while still pre-
venting cognitive decline by MB treatment.
MB application strategies for pro-aggregant full-length
TauΔK mice
In preventive treatment protocol (1), MB application
was initiated at 1.5mo of age and continued for 14.5mo
beyond the anticipated onset of cognitive deficits typically
around ~12mo of age in this mouse strain. The aim was
to target Tau-induced changes very early on, before any
neuropathological and cognitive changes occur (Figure 1a,
preventive MB for 14.5mo).
In preventive treatment protocol (2), MB administration
was initiated at 9mo of age, a time point ~3mo before the
expected onset of cognitive impairment but with presence
of early TauΔK-induced pathological changes such as con-
formational change, missorting and phosphorylation of
Tau (Figure 1a, preventive MB for 6mo).
Finally, therapeutic treatment protocol (3) aimed to
test whether therapeutic intervention by MB after onset
of cognitive decline has the potential to rescue the existingneuropathology and phenotype (Figure 1a, therapeutic
MB for 3mo). Therefore MB application was initiated at
15mo of age (~3mo after onset of cognitive impairments)
and continued for 3mo. In this respect, treatment protocol
(3) was closely analogous to the aforementioned Tau
switch-off experiments, which resulted in a complete res-
cue of functional deficits [14,15]. All TauΔK mice were
treated using an oral daily dose of 20 mg/kg MB, which
was administered via the drinking water.
MB application strategies for pro-aggregant repeat domain
TauRDΔK mice
Similar to TauΔK animals, TauRDΔK mice received MB
(20 mg/kg) for 14.5mo, starting at 1.5mo of age, long be-
fore the appearance of Tau pathology and cognitive im-
pairments (Figure 1b, protocol 1, preventive MB for
14.5mo).
In therapeutic treatment protocol (2), MB (20 mg/kg)
application started at 15mo of age and continued for
3mo (Figure 1b, therapeutic MB for 3mo). At the age of
15mo, TauRDΔK mice exhibit strong neuropathological
changes as described above and show severe learning
and memory deficits.
Finally, TauRDΔK mice received an excessive MB dose of
40 mg/kg for 3mo at the age of 12-15mo to further evalu-
ate the effect of MB on TauRDΔK aggregation (Figure 1b,
therapeutic protocol (3), excessive MB for 3mo).
After MB treatment, mice were tested for their general
motor and exploration behavior using an open field test
and for their spatial reference learning and memory per-
formance in a Morris water maze (MWM) test. In the
open field test, no differences between MB-treated and
untreated pro-aggregant Tau mice or wild-type (WT)
mice were observed for average velocity and distance
covered throughout all experimental setups. In addition
swimming speed did not differ between these groups in
the MWM test. Thus, we exclude that motor deficiencies
of pro-aggregant Tau mice account for the differences
detected in behavioral readouts (see below). This issue
is of concern since some published Tau-transgenic mice
developed motor deficits caused by transgene expression
in the spinal cord due to Thy-1.2 or PrP promoters
[11,13], which is avoided here by the use of the CaMKIIα
promoter.
MB treatment of pro-aggregant full-length TauΔK mice
Preventive treatment starting 11mo before cognitive decline
In this protocol, MB treatment started shortly after birth
and long before the expected onset of cognitive decline
(~12mo), and continued beyond this for a total of
14.5mo (including the final month of behavioral testing,
Figure 1a).
Regarding open field activity, the 14.5mo MB treat-
ment resulted in significant group differences, such that
Figure 1 Oral MB treatment strategies of mice. (a) Full-lengthTauΔK mice received MB for 14.5mo starting at 1.5mo of age, before onset of Tau
pathological changes and cognitive decline (protocol 1, 1.5 mo Tau pathology, 14.5 mo preventive MB, 20 mg/kg), for 6mo starting at 9mo of
age, shortly before the onset of cognitive impairments (protocol 2, 9 mo Tau pathology, 6 mo preventive MB, 20 mg/kg) and for 3mo starting at
15mo of age, at a time point, when learning and memory deficits are already present (protocol 3, 15 mo Tau pathology, 3 mo therapeutic MB,
20 mg/kg). The constant expression of TauΔK throughout the entire life-span in the absence of doxycycline is depicted as red bar. The onset of
progressive cognitive failure starting ~12 months of age is represented by the dotted arrow. (b) TauRDΔK received MB for 14.5mo starting at the
age of 1.5mo, before onset of Tau pathology and cognitive impairment (protocol 1, 1.5 mo Tau pathology, 14.5 mo preventive MB, 20 mg/kg)
and for 3mo starting at 15mo of age, after the onset of cognitive decline (protocol 2, 15mo Tau pathology, 3mo therapeutic MB, 20 mg/kg). An
excessive MB dose of 40 mg/kg was applied for 3mo at the age of 12-15mo (protocol 3, excessive MB, 40 mg/kg). The constant expression of
TauRDΔK throughout life-span in the absence of doxycycline is depicted as orange bar. The onset of cognitive deficits starting ~10mo of age is
represented by the dotted arrow. Periods and initiation of MB treatment are indicated by blue bars and red circles on the time axis, including
period of behavioral testing during the final month (green box). The daily MB dose (20 or 40 mg/kg) for each treatment protocol is given in
brackets. MB was administered via the drinking water. MB: methylene blue; mo: months; B: behavior tests; expr.: expression.
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MB-treated TauΔK mice (Figure 2a, p = 0.004, Additional
file 3: Figure S3). In contrast, no group differences
were observed for anxiety-related parameters (time in
center, distance to wall), suggesting that preven-
tive MB treatment did not have anxiolytic effects
(Additional file 4: Figure S4).
During MWM acquisition, WT mice and MB-treated
pro-aggregant full-length TauΔK mice showed a superior
learning performance over untreated TauΔK mice (WT vs.
TauΔK - MB: p = 0.025). Importantly, MB-treated TauΔK
mice demonstrated a similar learning efficiency than WT
animals (WT vs. TauΔK + 14.5mo MB: p = 0.532) and per-
formed significantly better than untreated TauΔK at day 4
and day 5 (TauΔK - MB vs. TauΔK + 14.5mo MB; day 4:p = 0.025; day 5: p = 0.018) (Figure 3a). In probe trials,
MB-treated TauΔK mice exhibited a higher preference for
the target quadrant and a more precise localization of the
target platform position in comparison to untreated TauΔK
mice (Additional file 5: Figure S5). The results indicate a
preservation of cognitive abilities upon preventive MB
treatment initiated before the onset of Tau pathological
changes and cognitive decline. Interestingly, WT mice re-
ceiving MB for 14.5mo, showed a slightly superior learn-
ing performance over untreated WT mice (Figure 3a),
pointing towards an additional beneficial effect of MB on
brain metabolism.
MB application for 14.5mo (started at 1.5mo of age)
reduced insoluble TauΔK and endogenous mouse Tau, com-
pared with untreated TauΔK mice (Figure 4). Similarly,
Figure 2 Exploration behavior of MB-treated TauΔK mice. Total activity (%) within 15 min is analyzed by an open field test after various MB treatment
periods. (a) Preventive MB treatment for (a) 14.5mo and for (b) 6mo results in preservation of exploration behavior of TauΔK mice similar to wild-type
(WT) animals, whereas untreated TauΔK mice show a significantly reduced activity. By contrast no group-differences are observed after therapeutic MB
treatment for 3mo (c). Bars represent mean values ± SEM. Statistics: one-way analysis of variances with post-hoc Newman-Keuls multiple comparisons
test. Asterisks indicate significant differences between groups; *: p < 0.05; **: p < 0.01; mo: months.
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MC1, 5-15 + 312-322, Figure 5, Additional file 6: Figure
S6) and a reduction of phosphorylated Tau (epi-
tope AT180, pThr231 + pSer235 and epitope PHF1,
pSer396 + pSer404) was observed after 14.5mo MB treat-
ment (Figure 5, Figure 6, Additional file 6: Figure S6).
By contrast, Tau phosphorylated at the KXGS motifs in-
side the repeat domain (epitope 12E8, pSer262 + pSer356)
was increased in MB-treated animals (Figure 6). Note that
Tau phosphorylation at the KXGS motifs causes detach-
ment of Tau from microtubules, but also protects Tau
against aggregation [51].
Previously, we described a close relationship between
expression of pro-aggregant Tau, synaptic failure inside
the hippocampus formation and cognitive decline [14,15].
While untreated pro-aggregent TauΔK mice showed a
consistent reduction in pre- and postsynaptic proteins
(i.e. synapsin 1, synaptophysin, PSD95), MB treatment
for 14.5mo preserved pre- and postsynaptic protein
levels (Figure 7), suggesting a protective effect of MB
on the synaptic integrity which likely contributes to the
preservation of cognition.
Clearance of proteins via autophagy is a major pathway
to maintain neuronal homeostasis and health. Preventive
MB treatment of TauΔK mice for 14.5mo increasedlevels of beclin, heat shock cognate protein 70 (HSC70)
and lysosome-associated membrane protein 2a (Lamp2a)
(Figure 8), indicating an upregulation of autophagy. While
beclin is involved in the initiation of the autophagosome
formation during macroautophagy, HSC70 (a constitu-
tively expressed molecular chaperone) and Lamp2a
(lysosomal receptor) play a role in chaperone-mediated
autophagy (CMA) of Tau (Wang et al., 2009). Another
prominent pathway for protein degradation is the
ubiquitin-proteasome system. As judged by an in-
creased level of PSMD13 (regulatory subunit of the 26S
proteasome), 14.5mo MB treatment enhanced prote-
asome function in comparison to WT and untreated
TauΔK mice (Figure 8). Taken together, the tendency of
MB to preserve or enhance protein degradation may
counteract the continuous accumulation of toxic Tau
species and contribute to maintenance of protein
homeostasis.
MB’s role as electron carrier and thus redox-cycling
compound is widely discussed in the literature [52]. How-
ever, we did not detect obvious differences between MB-
treated and untreated TauΔK mice regarding mitochondria
distribution and proteins of the electron transport chain
(Additional file 7: Figure S7), indicating that MB did not
alter this route of neuronal energy production.
Figure 3 Spatial learning of MB-treated TauΔK mice. Morris water maze (MWM) acquisition shows spatial learning abilities as indicated by path
lengths (cm) of mice after MB application using different preventive and therapeutic treatment paradigms. Significant group differences are
observed between untreated TauΔK mice and WT animals throughout all experiments, demonstrating impaired learning abilities upon expression
of pro-aggregant Tau (a-c). By contrast TauΔK mice treated with MB for 14.5mo (a) and 6mo (b) behave comparable to controls indicating preservation
of cognitive functions. Short-term MB treatment for 3mo has no beneficial impact on the learning performance of TauΔK mice (c). Data shows mean
path length ± SEM. Statistics: two-way repeated measure analysis of variances with post hoc Fishers LSD multiple comparisons test. Asterisks indicate
differences between MB-treated and untreated TauΔK mice; *: p < 0.05; n: number of mice.
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an early age the cognitive abilities of TauΔK mice were
essentially preserved, well beyond the expected onset
of decline and in spite of the continued expression of
the toxic mutant full-length TauΔK.Preventive treatment starting 3mo before cognitive decline
Preventive MB administration (protocol 2, started ~3mo
before onset of cognitive decline and continued for
6mo) showed an increase of open field activity of TauΔK
mice in comparison to the reduced activity of untreated
TauΔK mice (Figure 2b, Additional file 3: Figure S3). No
group differences concerning anxiety related parameters
were observed (Additional file 4: Figure S4). In MWM ac-
quisition, both untreated TauΔK and 6mo MB-treated
TauΔK mice performed less well than WT mice (WT vs.
TauΔK - MB: p = 0.017; WT vs. TauΔK + 6mo MB: p= 0.036,
Figure 3b). However, TauΔK mice with 6mo MB application
showed a better learning performance compared to un-
treated TauΔK on day 4 (TauΔK - MB vs. TauΔK + 6mo
MB: p = 0.042, Figure 3b). In addition they were able to
localize the target quadrant and platform position more
precisely than untreated TauΔK animals (Additional file
5: Figure S5), implying a minor beneficial effect of MB
on cognition.Neuropathological analysis revealed a reduction of
insoluble TauΔK and mouse Tau (Figure 4), a decrease
of conformationally-changed Tau (MC1) and phos-
phorylated Tau (AT180, PHF1) after 6mo of MB ad-
ministration (Figure 5, Figure 6, Additional file 6:
Figure S6). In addition, synaptic and autophagy marker
proteins as well as the proteasome marker PSMD13
were increased after 6mo MB (Figure 7, Figure 8) but
mitochondria remained unaffected (Additional file 7:
Figure S7).
Thus, if preventive treatment was started at adult age
with progressive tau pathology but still before the antici-
pated onset of cognitive decline, cognitive abilities were
protected to a certain extent, in spite of the continued
expression of toxic TauΔK.
Therapeutic treatment starting 3mo after cognitive decline
Finally, we tested the therapeutic potential of MB to re-
verse cognitive deficits ~3mo after onset (Figure 1a, proto-
col 3). MB treatment for 3mo did not enhance open field
activity of TauΔK mice. Thus, treated TauΔK mice behaved
similarly to untreated TauΔK animals (Figure 2c). WT mice
showed a slight but non-significant increase in open field
activity compared to transgenic animals, which was most
pronounced within the first 5 minutes of the experiment
(Additional file 3: Figure S3) and probably due to an
Figure 4 MB treatment reduces detergent insoluble TauΔK and mouse Tau. Sarcosyl-extraction of soluble and insoluble Tau from cortex tissue.
(a) Protein levels of soluble and insoluble Tau species in untreated TauΔK mice compared to TauΔK mice receiving MB for 14.5mo, 6mo and 3mo
detected by the pan-Tau antibody K9JA and the human Tau specific antibody TauY9. MB administration reduces levels of detergent-insoluble
human and mouse Tau. (b) Quantification of soluble Tau levels in cortex lysates shows a minor but non-significant decrease of soluble Tau
species upon MB treatment. (c) Quantification of insoluble Tau levels in cortex lysates demonstrates a clear decrease of insoluble human and
mouse Tau in MB-treated mice. Bars represent mean protein densities (%) ± SEM; statistics: one-way analysis of variances with post-hoc Newman-Keuls
multiple comparisons test. Asterisks indicate significant differences in comparison to untreated TauΔK mice; **: p < 0.01; Ab: antibody; mTau: mouse Tau;
n, number of samples.
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Figure 5 Histological analysis of conformationally changed and phosphorylated Tau in MB-treated mice. (a-e) MC1 immunoreactivity (epitope 5-15 +
312-322) indicates a pathological Tau conformation. MC1 positive neurons are prominent in somatosensory cortex (SSCx) of untreated TauΔK mice with
missorting of Tau to cell soma (arrows) and apical dendrites (arrowheads). In contrast MB treatment, especially preventive MB treatment for 14.5mo,
clearly reduces MC1 immunoreactivity in TauΔK mice. (f-j) Histological analysis of phosphorylated Tau using the AT180 antibody (dual phosphorylation
epitope pThr231 + pSer235). Untreated TauΔK mice display a massive mislocalization of phosphorylated Tau to cell soma (arrows) and apical dendrites
(arrowheads) of SSCx neurons, whereas MB treatment diminishes the extent of AT180 phosphorylation. Scale bar: 50 μm.
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parameters were unaffected (Additional file 4: Figure S4).
An MWM test indicated a severe learning impairment
of 3mo MB-treated TauΔK mice similar to untreated
TauΔK mice and in contrast to WT animals, which im-
proved consistently on each acquisition day (WT vs.
TauΔK - MB: p = 0.001; WT vs. TauΔK + 3mo MB: p = 0.011,
Figure 3c). In addition, MB-treated mice did not show any
preference for the target quadrant (Additional file 5: Figure
S5), underlining the persistence of cognitive deficits after
3mo MB.
Nevertheless, in spite of the failure in improving cognitive
defects, MB treatment was still able to reduce sarcosyl-
insoluble Tau, although to a minor extent in case of TauΔK
compared to preventive MB treatment paradigms (Figure 4).
In addition, conformationally changed Tau (MC1) and
phosphorylated Tau (AT180, PHF1) were clearly reduced
after 3mo MB treatment (Figure 5, Figure 6, Additional
file 6: Figure S6).
By contrast, the 3mo MB application was not able to re-
verse the decline of presynaptic markers synaptophysin
and synapsin 1 and the protective effect on postsynaptic
PSD95 was less pronounced than in preventive MB treat-
ment protocols (Figure 7). These results point towardssustained synaptic malfunction, which may underlie cogni-
tive impairment independently of the reversal of biochem-
ical Tau parameters. In addition, 3mo MB treatment only
partly affected protein degradation systems. Whereas an in-
crease in beclin and Lamp2a levels was detected, levels of
HSC70 and PSMD13 were comparable to untreated age-
matched TauΔK mice (Figure 8). As before, no effect on
mitochondria was observed (Additional file 7: Figure S7).
Preventive and therapeutic MB treatments of TauRDΔK
mice
In contrast to full-length TauΔK mice, animals expressing
the repeat domain TauRDΔK develop a pronounced brain
pathology in terms of Tau aggregation (neurofibrillary tan-
gles) and neuronal loss and exhibit an earlier onset of cog-
nitive decline ~10mo of age. This is consistent with the fast
aggregation of the protein in vitro caused by the higher
propensity for β-structure, and the absence of the N-and C-
terminal flanking domains (Additional file 1: Figure S1). As
in the case of full-length TauΔK, we tested different treat-
ment protocols for TauRDΔK mice (Figure 1b).
We performed preventive MB treatment for 14.5 mo,
starting at 1.5mo of age, long before onset of cognitive
decline (Figure 1b, protocol 1), as well as therapeutic
Figure 6 (See legend on next page.)
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Figure 6 MB application alters levels of phosphorylated Tau. (a) Levels of total Tau (pan-Tau antibody K9JA), PHF1 phosphorylated (epitope
pSer396/pSer404) and 12E8 (epitope pSer262/pSer356) phosphorylated Tau in cortex homogenates of MB-treated and untreated TauΔK mice.
MB administration for 14.5mo, 6mo and 3mo results in a decrease of PHF1 phospho-Tau as compared to untreated TauΔK mice. By contrast an
increase of 12E8 phospho-Tau inside the repeat domain of Tau is observed after MB treatment, indicating detachment from microtubules.
(b) Determination of relative protein densities by quantification of (a). Levels of phosphorylated Tau were normalized to total Tau levels. Bars
represent mean values ± SEM. Statistics: one-way analysis of variances with post-hoc Newman-Keuls multiple comparisons test. Asterisks indicate
significant differences in comparison to untreated TauΔK mice; *: p < 0.05; n, number of samples.
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decline (at age 15 mo) (Figure 1b, protocol 2). Both
treatments failed to decrease the level of insoluble Tau
(exogenous and endogenous, Additional file 8: Figure
S8) and did not protect synapses or induce protein deg-
radation via autophagy (data not shown).
Surprisingly, even long-term preventive treatment of
TauRDΔK mice (14.5mo) failed to reverse Tau-induced cog-
nitive deficits (Figure 9). MB-treated TauRDΔK mice did
not learn the location of the hidden platform, similar to un-
treated TauRDΔK animals (Figure 9a), and did not show a
significant preference for the target quadrant in subsequent
probe trials during MWM (Figure 9b). Thus, 20 mg/kg/
day MB was not sufficient to suppress Tau aggregation and
subsequent neurotoxic processes initiated by TauRDΔK.
To investigate whether higher doses of MB would in-
fluence TauRDΔK pathology, the mice were treated with
an excessive dose of MB (40 mg/kg/day MB) for 3mo
(Figure 1b, protocol 3, ~12-15mo of age, after cognitive
decline). This actually resulted in an increase of aggre-
gated Tau species in the hippocampus of TauRDΔK mice
as detected by sarcosyl extraction and Gallyas silver
staining (Figure 10). However, phosphorylated Tau was
unaltered and autophagy partly reduced (data not
shown). This detrimental effect of high doses MB was
further confirmed by cell culture experiments. Inducible
N2a cells expressing pro-aggregant TauRDΔK [53] accu-
mulated aggregated Tau species in response to high con-
centrations of MB (25-100nM) in a dose-dependent
manner (Additional file 9: Figure S9). Especially MB
concentrations >100nM caused a massive loss of N2a
cells, indicating a toxic gain of function in cells.Discussion
In this study we analyzed different protocols to determine
optimal conditions for the preservation of cognitive
abilities in pro-aggregant Tau transgenic mice treated
with the Tau-aggregation inhibitor Methylene Blue
(MB). Pro-aggregant full-length human TauΔK or repeat
domain TauRDΔK was expressed in inducible transgenic
mice from birth onwards, leading to onset of cognitive
decline at ~12mo or 10mo, respectively. The questions
to be tested were: can treatment before the expectedonset prevent the cognitive decline? Can treatment
after the onset rescue the decline?
The results show that (1) MB preserves cognition in
full-length pro-aggregant TauΔK mice upon preventive
treatment, provided that the intervention starts before
the onset of behavioral deficits, whereas treatment initi-
ated after onset of cognitive decline does not rescue. In
addition, preventive MB application starting at young
age (~1.5mo) has a greater impact on the cognitive per-
formance than preventive MB application initiated at ad-
vanced age (~9mo) but shortly before onset of cognitive
impairments. (2) MB reduces Tau aggregation, Tau phos-
phorylation and pathological Tau conformation in TauΔK
mice. (3) MB protects synapses and enhances protein
degradation by autophagy but has no obvious effect on
mitochondria in TauΔK mice. (4) MB fails to prevent
cognitive deficits in pro-aggregant repeat domain
TauRDΔK mice, even when applied shortly after birth,
presumably because the high aggregation propensity of
TauRDΔK overwhelms the protective actions of the
drug. (5) MB administered at high doses increases Tau
aggregation rather than counteracting it.Absorption and distribution of MB in mice
Methylene blue was well tolerated in wild-type mice
after oral application and reached plasma and brain con-
centrations beyond the detection level over a time
course of 24 h. At 24 h post application, MB brain levels
were ~30-60-fold higher as compared to MB plasma
levels after i.v. and oral administration, respectively. The
data demonstrates that MB is well absorbed, readily
crosses the blood-brain barrier and concentrates in the
nervous tissue, confirming earlier reports of MB
pharmacokinetics in mice [39]. In good agreement to
previous studies analyzing pharmacokinetic profiles of
MB in humans [54,55], MB peak-levels in plasma and
brain were observed 1-2 h after oral intake. In this study,
MB plasma half-life times of 4-5 h and brain half-life
times ~3 h or ~30 h were calculated after i.v. or oral MB
application. In comparison, human MB plasma half-life
times in the range of ~5-6 h [2,54] to ~18 h [55] were
determined, whereas half-life times in human brains are
not available. In addition the total bioavailability of MB
Figure 7 Recovery of synaptic marker proteins in hippocampus of MB-treated mice. (a) Levels of pre- and post-synaptic proteins synaptophysin,
synapsin 1 and postsynaptic density 95 (PSD95) in hippocampus lysates of age-matched untreated and MB-treated TauΔK mice. β-actin serves as
loading control. (b) Determination of relative protein densities by quantification of (a). Untreated TauΔK mice show a constant decrease of synapsin 1,
synaptophysin and PSD95 levels in comparison to WT, due to constant expression of pro-aggregant TauΔK. In contrast a recovery of pre- and
postsynaptic markers is observed after preventive MB application for 14.5mo and 6mo, whereas therapeutic MB treatment for 3mo causes a
partial rescue of post- but not of presynaptic markers. Protein levels were normalized to β-actin. Bars represent mean values ± SEM. Statistics:
one-way analysis of variances with post-hoc Newman-Keuls multiple comparisons test. Asterisks indicate significant differences in comparison
to untreated TauΔK mice; *: p < 0.05; **: p < 0.01; n, number of samples.
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humans (~70%, [55]). These variations may arise from
different absorption and distribution properties of MB
in rodents, which further complicate a direct comparison
of human and rodent MB dosing despite FDA surface areaconversion tables [56]. Furthermore, pharmacokinetic
analyses presented in this study reflect absorption and
distribution of MB in wild-type mice, which may
slightly differ in aged TauΔK and TauRDΔK animals.
Since Tau transgenic mice develop an age-dependent
Figure 8 Preventive MB administration increases protein degradation. (a) Levels of autophagy- (beclin, HSC70), lysosome- (lamp2a), and
proteasome-related (PSMD13) proteins in hippocampus lysates of age-matched untreated TauΔK mice compared to MB-treated TauΔK mice for
14.5mo, 6mo and 3mo. β-actin serves as loading control. (b) Quantification of (a). While both preventive MB treatment strategies (14.5mo and
6mo MB) increase levels of beclin, HSC70, Lamp2a and PSMD13, therapeutic MB treatment for 3mo leads to a partial increase of beclin and
Lamp2a whereas levels of HSC70 and PSMD13 remain unaffected in comparison to untreated TauΔK mice. Protein levels were normalized to β-
actin. Bars indicate mean values ± SEM. Statistics: one-way analysis of variances with post-hoc Newman-Keuls multiple comparisons test. Asterisks
indicate significant differences in comparison to untreated TauΔK mice; *: p < 0.05; **: p < 0.01; ***: p < 0.001; n, number of samples.
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permeability cannot be excluded.
MB’s therapeutic potential depends on the time point of
intervention and Tau aggregation
Tau aggregation requires detachment of Tau from mi-
crotubules, which is increased by Tau phosphorylation
inside the repeat domain [57]. Especially disease- and
stress-related conditions induce mislocalization of un-
bound Tau into postsynaptic sites, which is connected to
increased phosphorylation and aggregation of Tau and
impaired microtubule interactions [58,59]. In further
consequence, accumulation of phosphorylated Tau indendritic spines causes functional impairments, which fi-
nally lead to the loss of synapses [60].
The process of Tau aggregation includes several stages:
the repeat-domain of Tau contains motifs with increased
tendency to form β-structures, which function as
aggregation-prone templates and are enhanced by muta-
tions such as ΔK280 [61]. In seeded assembly, Tau nuclei
trigger further aggregation by interaction with other Tau
repeat domains from both exogenous human and en-
dogenous mouse Tau, resulting in the co-assembly into
neurofibrillary tangles.
After switch-off, the synthesis of new pro-aggregant β-
structure seeds is blocked, while existing aggregates
Figure 9 Preventive MB treatment does not rescue cognitive decline of TauRDΔK mice. MWM test shows cognitive abilities of TauRDΔK mice after
preventive MB application for 14.5mo. (a) MB-treated as well as untreated TauRDΔK animals show impaired learning abilities similar to untreated
TauRDΔK littermates, as indicated by increased path lengths to reach the hidden platform in MWM acquisition in comparison to WT. Data shows
mean path length ± SEM. (b) Preventive MB treatment for 14.5mo does not result in a higher preference of the target quadrant as compared to
untreated TauRDΔK mice and controls. Bars represent mean values ± SEM. Statistics: two-tailed one sample t-test against chance level of 25%; *: p < 0.05;
**: p < 0.01; n = number of animals; T: target quadrant; R: right quadrant; O: opposite quadrant; L: left quadrant; LTPT: long-term probe trial.
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by the intracellular machinery. However, endogenous
mouse Tau is still continuously expressed and can be in-
corporated into existing seeds and polymers. Thus the
remaining aggregates mainly consist of mouse Tau,
which is less toxic to synapses [14].
According to this scheme, removing or blocking amyloi-
dogenic Tau counteracts Tau pathology. As a consequence
of this “genetic treatment”, cognitive impairment can be
rescued by an overall elimination of toxic Tau, even after
cognitive decline has set in. This holds for both models,
pro-aggregant full length Tau (TauΔK) and repeat domain
Tau (TauRDΔK) [14,15]. By contrast, aggregation inhibitors
such as MB interfere with the aggregation process but do
not affect de novo synthesis of pro-aggregant toxic Tau.
This allows the formation of new β-structured seeds, which
continue to aggregate. This would explain why MB can pre-
vent pathology if administered at an early time point (be-
cause this keeps the seeds for aggregation below a critical
threshold) but is inefficient if administered too late.
Several studies have confirmed the efficacy of MB in
models of tauopathy when administered at early time
points. A recovery of Tau-induced pathology and relatedlocomotor phenotype was reported for a C. elegans
model of tauopathy [35]. In Tau transgenic mice im-
provements of learning and memory behavior as a con-
sequence of MB application was reported for Tau-P301S
mice [62] and rTg4510 (Tau-P301L) mice [39]. In the
successful treatment protocol used by Stack et al. (2014),
MB (4 mg/kg/day) was administered for 10mo, starting
at 1mo of age. Typically, Tau-P301S mice (line PS19) de-
velop cognitive deficits ~6mo of age [8,63]. Thus, MB
treatment was initiated ~5mo before the onset of cogni-
tive impairment, and therefore this can be considered as
a preventive strategy. O’Leary et al. (2010) reported an
improved cognitive performance of rTg4510 mice after
3mo of MB treatment (10 mg/kg/day) starting at 3mo of
age. Both studies are consistent with our results, which
demonstrate a beneficial effect of MB in TauΔK mice,
when administered using preventive application strategies.
The data underscores the need of early biomarkers
(e.g. from cerebrospinal fluid, brain imaging, etc.), which
would identify asymptomatic patients at a point where
toxic Tau aggregates have not yet reached a critical
level, so that aggregation inhibitors have a chance to
keep them from becoming super-critical [64,65].
Figure 10 High MB-doses increase Tau aggregation. (a) Sarcosyl-extraction of insoluble Tau from cortex tissue of TauRDΔK mice. MB application
using a daily dose of 40 mg/kg for 3mo results in an increase of sarcosyl-insoluble human TauRDΔK and endogenous mouse Tau (antibody K9JA).
(b) Quantification of (a) shows a ~2-3 fold increase of insoluble Tau after high-dose MB treatment for 3mo. Bars represent mean values ± SEM.
Statistics: two-tailed t-test; *: p < 0.05; **: p < 0.01; n, number of samples. (c, d) Gallyas silver staining of Tau aggregates shows an increase of
tangle-positive cells inside the hippocampus formation of MB-treated TauRDΔK mice (40 mg/kg for 3mo). Scale bar: 200 μm. Boxed areas indicate
close-ups presented in (e-j). Higher magnification of dentate gyrus (DG), CA3 and CA1 hippocampal areas of untreated TauRDΔK mice (e-g) in
comparison to corresponding areas of MB-treated TauRDΔK mice (h-j). CA3: region III cornus ammonis; CA1: region I cornus ammonis. Scale
bar: 40 μm.
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Why is MB able to counteract the pathology of full-
length TauΔK but not that of repeat domain TauRDΔK?
Removal of the flanking domains outside the repeats of
Tau is known to enhance Tau aggregation [53,66,67] be-
cause this exposes the pro-aggregant hexapeptide motifs
of Tau which are normally shielded by the N- and C-
terminal domains [68]. Tau aggregates of repeat domain
TauRDΔK mice are positive for the amyloid marker
thioflavin S, and fibers can be visualized by electron
microscopy. By contrast, mice expressing full-lengthTauΔK lack these characteristics because this protein
aggregates more slowly, has a low expression level, and
does not reach the stage of mature Gallyas-positive
tangles inside the hippocampus. Nevertheless, the
“pre-tangles” contain smaller aggregates and oligo-
mers, which are sufficient to cause synaptic decay and
cognitive decline, with later onset than mice expressing
the repeat domain.
Figure 11 illustrates a hypothetical progression model
for both full-length TauΔK and repeat domain TauRDΔK
mice. In both models, progressive Tau aggregation (red
Figure 11 Models of MB interference during disease progression in full-length TauΔK and repeat domain TauRDΔK mice. (a) In TauΔK mice unaltered
Tau aggregation due to continuous expression and accumulation of toxic Tau reaches the threshold of cognitive impairment at the age of ~12mo.
Once the “point of no return” is passed, TauΔK mice exhibit cognitive impairments and synaptic decay [15]. Preventive application of MB, starting before
the critical threshold is reached, efficiently interferes with TauΔK aggregation. Thus, the disease progression is slowed down and the onset of cognitive
decline postponed. However, therapeutic MB application initiated at 15mo of age, beyond the “point of no return” and after the onset of cognitive
impairment, is not able to rescue the cognitive phenotype. By contrast, “genetic treatment” by TauΔK switch-off can reduce aggregation and
reverse the cognitive decline. (b) TauRDΔK exhibits stronger aggregation properties than TauΔK, due to a higher β-propensity. Thus, TauRDΔK
mice show a faster disease progression with onset of cognitive decline ~10mo of age [14]. MB’s anti-aggregation properties are not strong
enough to efficiently retard the aggregation process, even if applied at early age (1.5mo). Consequently, the “point of no return” is barely
delayed in TauRDΔK mice, and therapeutic treatment is ineffective. Similar to TauΔK, genetic treatment by TauRDΔK switch off is still able to
reverse the cognitive phenotype even after onset of cognitive impairment. Red line: unaltered progression of Tau aggregation; green line:
threshold of cognitive impairment; black X: “point of no return”; solid black lines: MB treatment periods of mice; magenta lines: “genetic treatment” by
switch off of Tau expression; B, green boxes: behavior tests and termination of experiments; dotted black lines: assumed further progression of Tau
aggregation; (1, 2, 3): MB treatment protocols according to Figure 1; mo: months.
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threshold indicating the onset of cognitive impairment
(“point of no return”, marked by X, Figure 11a,b). In the
case of pro-aggregant full-length TauΔK mice, the “point of
no return” is reached at the age of ~12mo (Figure 11a).
The slope of the aggregation can be reduced by MB (black
lines corresponding to treatment protocols 1, 2, 3). If this
takes place before the “point of no return”, cognitive im-
pairment is delayed to a much later age (protocols 1, 2). If
treatment starts after the “point of no return”, cognitive
decline cannot be rescued, in spite of the slower aggrega-
tion rate (protocol 3).
The principle in case of TauRDΔK is similar, with the
major difference that Tau aggregation is stronger and
leads to a faster disease progression with earlier onset
of cognitive deficits ~10mo of age (Figure 11b). Here
the anti-aggregation potential of MB is not strong
enough to retard Tau aggregation significantly and
postpone the onset of cognitive impairment, even if
treatment is started at early age (protocol 1). In contrast
to treatment with an aggregation inhibitor, “genetic
treatment” by switching-off TauΔK or TauRDΔK reverses
the slope (due to ongoing protein degradation) so that
cognitive decline can be rescued (Figure 11a + b, magenta
line, [14,15,69]).
Direct interference of MB and Tau
MB is a redox-recycling agent and interacts with ex-
posed cysteines, nucleotide-binding proteins and others;
this may explain its many uses in medicine [70]. With
regard to Tau, MB acts as an aggregation inhibitor
[24,25,30] by a mechanism based on the oxidation of
cysteine residues C291 and C322. They lie within the
Tau repeat domain and affect the conformations and
interactions leading to aggregation [71,72]. In addition,
MB has been reported to lower the level of Tau by
interacting with the chaperone hsp70 [73].
Beside MB (IC50: 1.9 μM, [24]), other potent Tau aggre-
gation inhibitors have been identified (reviewed in [21,74-
76]). Especially rhodanines (e.g. bb14, IC50 = 0.67 μM)
and phenylthiazolyl-hydrazides (PTHs, i.e. BSc3094,
IC50 = 1.6 μM) efficiently inhibit Tau aggregation and
show a low cytotoxicity in cell-based assays [77,78],
in C. elegans [35] or in hippocampal slice culture
models of tauopathy [79].
General effects of MB on cell metabolism
The fact that MB-treated WT mice show a somewhat
better learning performance compared to untreated WT
mice argues for a general increase in cell metabolism
or clearance of toxic proteins upon MB treatment. Es-
pecially modulation of autophagy and subsequent pro-
tein degradation via lysosomes is a promising
therapeutic target in neurodegenerative diseases sinceautophagy is a major pathway for the clearance of long-
lived and aggregated proteins [80,81]. Indeed, aggre-
gated forms of Tau are cleared preferentially by autoph-
agy [82]; however, the situation is less well defined for
toxic oligomeric forms of Tau where both degradation
pathways may contribute [83]. Several studies suggest
an effect of MB on different protein degradation path-
ways. While Congdon and colleagues show an mTOR-
dependent induction of macroautophagy mediated by
MB [44], Medina et al. (2011) report an increase of
chymotrypsin- and trypsin-like activities of the prote-
asome after MB treatment. In addition, inhibition of the
Hsp70 ATPase activity by MB facilitated chaperone-
mediated clearance of Tau [73].
The upregulation of different degradation mechanisms
by MB was also observed in our experiments, as judged
by different marker proteins. While upregulation of
beclin is related to increased macroautophagy, higher
levels of HSC70 and Lamp2a argue for an induction of
CMA, and the rise in PSMD13 points to an increase of
proteasome activity. In this respect, MB provides add-
itional beneficial effects which may enhance MB’s neuro-
protective properties. In contrast we were not able to
confirm a protective effect of MB in terms of oxidative
stress as described by others [62]. These discrepancies
may be due to the use of another transgenic mouse
model, which differs by cognitive phenotype as well as in
brain pathology.Importance of the dose
We and others [62] observed that high doses of MB
(40 mg/kg/day) are detrimental and rather increase path-
ology. A hormetic dose-response to MB is discussed in
the literature, suggesting that MB’s beneficial effect may
be limited to a certain range of concentration, whereas
concentrations below or beyond the optimal range are
ineffective or even lead to detrimental effects. In rats, an
optimum concentration of 4 mg/kg improves cognitive
function, whereas lower (1 mg/kg) and higher (10 mg/
kg) doses were ineffective [84]. In addition, an excessive
dose of 50 mg/kg resulted in a decrease of cognitive
functions below control levels, indicating a detrimental
effect of MB [84]. This hormetic dose-response was at-
tributed to MB’s auto-oxidizing properties. In vivo at
low concentrations (<5 μM), reduced MBH2 and oxidized
MB are in equilibrium and form a reversible reduction-
oxidation system, which functions as an electron cycler
and scavenger of free radicals. By this mechanism, MB has
the potential to donate electrons to the mitochondrial re-
spiratory chain, which finally increases energy production.
On the contrary, higher MB concentrations (>5-10 μM)
eliminate the equilibrium and electrons are taken away
from the respiratory chain. This results in inhibition of
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oxygen [85] or indirectly via inhibition of nitric oxide
synthase (NO) [86].
Currently attempts are underway to further improve
MB in terms of bioavailability and tolerance. A new for-
mulation of Rember™ named LMTX™ provides MB in a
stabilized, reduced “leuco-form”, which shows a higher
absorbance from the intestine and therefore increases
the effective dose of MB in the brain [4,33,34]. Another
strategy is the development of MB-loaded hydrophobic
nanoparticles suitable for blood-brain barrier permeation,
which may provide a steady-state drug release instead of
variable drug concentrations after intake of a single daily
dose [87].
Conclusion
In summary, we observed several effects of MB, which
may together contribute to the improvement of cogni-
tion in treated Tau-transgenic mice. The most crucial
parameters in our experiments are (i) the time point of
intervention and (ii) the aggregation propensity of Tau.
A preventive strategy (initiated before onset of cogni-
tive decline) can be successful, provided that the aggre-
gation propensity is not too strong, which is the case
for full-length TauΔK but not for TauRDΔK. However, in
neither case can the pathology be reversed by MB if
therapeutic treatment is started after the onset of cog-
nitive decline.
In other words, MB treatment is no longer effective
when the destruction of synaptic functions has already
progressed beyond the “point of no return”. The direct
effect of MB on Tau aggregation is one of the key events
in the defense against Tau-induced functional changes
since MB’s potency decreases with increasing β-propensity
of Tau. Additionally, beneficial side effects of MB that en-
hance neuronal cell metabolism reinforce the neuropro-
tective impact of MB.
Thus, our study supports the use of MB as Tau aggre-
gation inhibitor for treatment of AD and other tauopa-
thies but clearly emphasizes the need for early
preventive intervention prior to irreversible synaptic
damage.
Additional files
Additional file 1: Figure S1. Domains of human full-length TauΔK and
repeat domain TauRDΔK. Diagram of the domains of human full-length
TauΔK (2N4R, amino acids 1-441) and repeat domain TauRDΔK (amino acid
244-372). A pro-aggregant variant of TauΔK or TauRDΔK with deletion of
lysine 280 (ΔK280) is expressed in inducible Tau transgenic mice. The
hexapeptide motifs (PHF6*, PHF6) are located in the repeat domain (R1-
R4) and show a high tendency to form β-structure. Adapted from [27].
Additional file 2: Figure S2. Pharmacokinetic analysis of MB after
intravenous and oral application. (a) Profiles of TMT-ion concentrations
after intravenous (i.v.) application of 30 mg/kg MB in plasma (ng/ml, redcircles) and brain tissue (ng/g, blue squares) measured by LC-MS/MS over
24 h. For i.v. application, TMT-ion half-life times of t½ = 4.4 h in plasma
and t½ = 3.0 h in brain are determined. (b) Profiles of TMT-ion concentrations
after oral administration of 45 mg/kg MB in plasma (ng/ml, red circles) and
brain tissue (ng/g, blue squares) measured by LC-MS/MS over 24 h. For oral
administration, TMT-ion half-life times of t½ = 30.6 h in brain and t½ = 4.7 h in
plasma are calculated. Final TMT-ion concentrations at 24 h post application
are given in nM for each curve. Data represents mean values ± SEM, n = 3 per
time point. MB: methylene blue, TMT-ion: tetramethylionium-ion (= MB
without chloride and 3*H2O), LC-MS/MS: liquid chromatography – mass
spectrometry.
Additional file 3: Figure S3. Open field activity of MB-treated
mice within intervals. (a) Open field activity within 3 intervals à 5 min.
Untreated TauΔK mice show a decreased exploration behavior in
comparison to WT. Mice treated with MB for (a) 14.5mo and (b) 6mo show a
considerably higher activity within interval 2 and 3 as compared to untreated
TauΔK mice, whereas no difference between MB-treated and untreated
mice is observed for 3mo of MB application (c). Bars represent mean
values ± SEM.
Additional file 4: Figure S4. MB application does not influence anxiety-
related parameters. No differences are detected between untreated and
MB-treated TauΔK mice for anxiety-related parameters such as average
distance to wall (a) and total time in center (b) throughout all experimental
conditions, suggesting that MB does not exert anxiolytic properties. Bars
represent mean values ± SEM. Statistics: one-way analysis of variances
with post-hoc Newman-Keuls multiple comparisons test. n.s.: not significant.
Additional file 5: Figure S5. MWM long-time probe trial - localization
of the target platform. Preventive treatment with MB (14.5mo or 6mo)
results in a higher preference of the target quadrant in a long term probe
trial (a) and in a more precise localization of the target platform during
probe trials as indicated by time in target platform (b). In contrast
therapeutic MB application for 3mo does not increase the overall
preference of MB-treated TauΔK mice for the target quadrant, albeit it
seems to improve the ability to localize the platform position to some
extent, suggesting a minor effect of MB. Bars represent mean values ±
SEM. Statistics: (a) two-tailed one sample t-test against chance level of
25%; *: p < 0.05; **: p < 0.01; ***: p < 0.001; (b) two-way repeated measure
analysis of variances with post hoc Fishers LSD multiple comparisons test.
T: target quadrant; R: right quadrant; O: opposite quadrant; L: left quadrant;
PT: probe trial; LTPT: long-term probe trial.
Additional file 6: Figure S6. Histological analysis of conformationally
changed and phosphorylated Tau in MB-treated mice. (a-e) MC1 staining
(epitope 5-15 + 312-322) indicates a pathological Tau conformation in
somatosensory cortex neurons of untreated TauΔK mice with missorting
of Tau to cell soma and apical dendrites (b1-b3). In contrast MB treatment for
14.5mo (c1-c3), 6mo (d1-d3) and 3mo (e1-e2) reduces MC1 immunoreactivity
in TauΔK mice. Wild-type (WT) animals are MC1-negative (a1). Scale bar:
50 μm. n = 3 animals per condition. (f-j) Staining of phosphorylated Tau
(antibody AT180, dual phosphorylation epitope pThr231 + pSer235) in
somatosensory cortex of MB-treated and untreated TauΔK mice. Untreated
TauΔK mice exhibit numerous AT180-positive neurons with massive
mislocalization of phosphorylated Tau to cell soma and apical dendrites
(g1-g3), whereas MB treatment for 14.5mo (h1-h3), 6mo (i1-i3) and 3mo
(j1-j3) diminishes the extent of AT180 phosphorylation. Wild-type (WT)
animals are AT180-negative (f1). Scale bar: 50 μm. n = 3 animals per
condition.
Additional file 7: Figure S7. MB shows no influence on mitochondria
in CA3 region of the hippocampus. The intracellular distribution of
mitochondria in pyramidal neurons of the hippocampal CA3 region is
visualized by fluorescence confocal microscopy. Paraffin sections of
wild-type animals (a), untreated TauΔK mice (b) and MB-treated TauΔK
mice (c-e) were fixed and stained with OXPHOS antibody cocktail
(DyLight 650, red), which was used as a mitochondrial marker. Nuclei
were counterstained with Syto13 (green). No difference of mitochondrial
immunoreactivity was observed among WT animals and TauΔK mice with
or without MB treatment for the time period indicated. Scale bar: 10 μm.
Additional file 8: Figure S8. Administration of 20 mg/kg MB for 3mo
and 14.5mo does not influence insoluble Tau levels in TauRDΔK mice.
Hochgräfe et al. Acta Neuropathologica Communications  (2015) 3:25 Page 20 of 22Sarcosyl-extraction of insoluble Tau from cortex tissue of TauRDΔK mice.
MB administration using a daily dose of 20 mg/kg MB for (a) 3mo and
(b) 14.5mo does not alter levels of detergent-insoluble Tau in comparison
to untreated TauRDΔK mice as shown by the pan-Tau antibody K9JA. Ab:
antibody; mTau: mouse Tau.
Additional file 9: Figure S9. MB affects the amount of Tau4RDΔK280
protein in inducible N2a cells. (a) Inhibition of recombinant Tau3RD
aggregation by MB monitored in vitro by filter assay and Western blot
(adapted from [71]). (b) Examples of confocal micrographs of
Tau4RDΔK280 expressing N2a cells after 96 h incubation-/expression time.
(c) Western blot of the Tau load in Tau4RDΔK280 expressing N2a cells
treated with increasing methylene blue concentrations detected by pan-
Tau antibody K9JA (c1) and phosphorylation-depended antibody 12E8
(epitopes pSer262/pSer356) (c2). Expression of Tau4RDΔK280 in N2a cells is
induced by addition of doxycycline (1 μg/ml) (Tet-on system) as shown by the
pan-Tau antibody K9JA. Monomeric and oligomeric Tau is phosphorylated
at KXGS motifs inside the repeat domain as shown by Ab 12E8 (epitope
pSer262, pSer356). Incubation of N2a cells with increasing concentrations
of MB (25nM, 50nM or 100nM) for 4 days results in a dose-dependent
increase of oligomeric Tau species and a subsequent decrease of
monomeric Tau4RDΔK280. Monomeric Tau includes the entire Tau
repeat domain as well as truncated fragments (F2, F3). (d) Relative
quantification of (c1) shows the change in Tau protein densities
(monomeric vs. oligomeric Tau) upon treatment of cells with increasing
concentrations of MB.
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